Lung cancer drug lorbrena under Post-Market review
NCT ID NCT03844464
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This study tracked 1,290 people with non-small cell lung cancer who were already taking the drug Lorbrena. The goal was to learn more about side effects, especially brain and liver problems. Researchers wanted to see what factors might increase these risks. The study did not test if the drug worked, but rather gathered safety information after the drug was already on the market.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
3-22-7, Yoyogi, Shibuya-ku
Tokyo, 151-8589, Japan
Conditions
Explore the condition pages connected to this study.